Trial · NCT07885098
Effects of Tart Cherry and Aronia Extract Supplementation on Selected Physiological Parameters in Endurance-Trained Men
NCT07885098, Not applicable, Recruiting, Wroclaw Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Tart Cherry and Aronia Extract Supplementation on Selected Physiological Parameters in Endurance-Trained Men. Trials, record NCT07885098. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885098
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Tart Cherry and Aronia Extract Supplementation on Selected Physiological Parameters in Endurance-Trained Men
- NCT number
- NCT07885098
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Wroclaw Medical University
- Conditions
- Cardiovascular Physiology
- Interventions
- Standardized Tart Cherry and Aronia Extract, Placebo
- First posted
- 2026-10-21
- Last updated
- 2026-11-10
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in total peripheral resistance at rest | Baseline and Day 28 of each intervention period | Change in resting total peripheral resistance (TPR) from baseline to the end of each 4-week intervention period. TPR will be derived from continuous non-invasive arterial blood pressure recordings obtained during the resting supine recording. Lower values after intervention indicate a reduction in resting TPR. |
| Primary | Change in brachial artery flow-mediated dilation | Baseline and Day 28 of each intervention period | Change in brachial artery flow-mediated dilation (FMD), expressed as the percentage increase in maximal brachial artery diameter during reactive hyperemia relative to baseline diameter, from baseline to the end of each 4-week intervention period. |
| Secondary | Change in total peripheral resistance response to transient hypoxia | Baseline and Day 28 of each intervention period | Total peripheral resistance (TPR) response to hypoxia will be quantified as the absolute value of the slope of the regression line relating TPR to arterial oxygen saturation (SpO2) during the transient hypoxia test. For each nitrogen-breathing episode, one pre-hypoxic and one post-hypoxic point will be included. The pre-hypoxic point will represent mean SpO2 and mean TPR during the 40-second period preceding nitrogen administration. The post-hypoxic point will represent the SpO2 nadir and the corresponding minimum TPR value within a window extending from 10 seconds before to 30 seconds after the SpO2 nadir. The regression will be fitted using all pre- and post-hypoxic points obtained during the test. The slope will be expressed as an absolute value; therefore, a higher value indicates a greater reduction in TPR in response to a given decrease in SpO2 and thus a stronger vascular response to hypoxia. |
| Other | Change in hypoxic ventilatory response | Baseline and Day 28 of each intervention period | Hypoxic ventilatory response (HVR) will be quantified as the absolute value of the slope of the regression line relating inspiratory minute ventilation (VI) to arterial oxygen saturation (SpO2) during the transient hypoxia test. For each nitrogen-breathing episode, the pre-hypoxic point will represent mean SpO2 and mean VI during the 40-second period preceding nitrogen administration. The post-hypoxic point will represent the SpO2 nadir and the mean of the three highest VI values within a window extending from 10 seconds before to 30 seconds after the SpO2 nadir. The regression will be fitted using all pre- and post-hypoxic points obtained during the test. The slope will be expressed as an absolute value, with higher values indicating greater peripheral chemosensitivity. |
| Other | Change in peak oxygen uptake (VO2peak) | Baseline and Day 28 of each intervention period | Change in peak oxygen uptake (VO2peak) from baseline to the end of each 4-week intervention period. VO2max will be determined during symptom-limited cardiopulmonary exercise testing performed on a cycle ergometer using an individualized ramp protocol with continuous analysis of respiratory gases. |
| Other | Change in the standard deviation of normal-to-normal RR intervals (SDNN) | Baseline and Day 28 of each intervention period | Change in the standard deviation of normal-to-normal RR intervals (SDNN) from baseline to the end of each 4-week intervention period. SDNN will be derived from resting electrocardiographic recordings as a time-domain measure of heart rate variability. |
| Other | Change in plasma asymmetric dimethylarginine concentration | Baseline and Day 28 of each intervention period | Change in plasma asymmetric dimethylarginine (ADMA) concentration from baseline to the end of each 4-week intervention period. ADMA is assessed as a circulating marker related to nitric oxide bioavailability and endothelial function. |
| Other | Change in Interleukin-6 | Baseline and Day 28 of each intervention period | Change in plasma interleukin-6 (IL-6) concentration from baseline to the end of each 4-week intervention period. |
| Other | Change in skin advanced glycation end-products | Baseline and Day 28 of each intervention period | Change in skin advanced glycation end-products (AGEs) from baseline to the end of each 4-week intervention period. Tissue accumulation of AGEs will be assessed non-invasively by measurement of skin autofluorescence at the forearm. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885098
GET https://conductscience.org/api/trials/v1/NCT07885098/registered